HS
NKTR icon

HighVista Strategies’s Nektar Therapeutics NKTR Stock Holding History

HighVista Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
14,555
+2,806
+24% +$160K 0.29% 111
2025
Q4 		$497K Buy
+11,749
New +$658K 0.13% 142

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HighVista Strategies's NKTR Position: Q1 2026 in Review

HighVista Strategies increased its Nektar Therapeutics (NKTR) stake by 24% in Q1 2026, buying an estimated $160K and bringing the position to 14,555 shares worth $1.05M. The position accounts for 0.29% of the portfolio, ranked #111.

HighVista Strategies first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • HighVista Strategies held 14,555 shares of Nektar Therapeutics worth $1.05M as of Q1 2026.
  • HighVista Strategies bought 2,806 Nektar Therapeutics shares in Q1 2026, an estimated $160K.
  • Nektar Therapeutics made up 0.29% of HighVista Strategies's portfolio in Q1 2026, its #111 holding.
  • HighVista Strategies first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.